Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?

Area of Science:

• Neonatal Medicine
• Pediatric Hematology
• Critical Care

Background:

• Intraventricular hemorrhage (IVH) is a significant complication in premature infants.
• Antithrombin III (AT-III) is a protein involved in blood coagulation.
• The potential prophylactic role of AT-III in preventing IVH in neonates remains unclear.

Purpose of the Study:

• To investigate the efficacy of antithrombin III in reducing the incidence of intraventricular hemorrhage in premature infants.

Main Methods:

• A randomized controlled trial involving 60 infants born before 30 weeks of gestation.
• Infants were assigned to receive either a loading dose of antithrombin III or a placebo.
• Coagulation parameters including partial thromboplastin time, Quick's prothrombin time, and platelet count were monitored.

Main Results:

• No statistically significant difference in the incidence of intraventricular hemorrhage was observed between the antithrombin III group (27.5%) and the placebo group (32%).
• Key coagulation markers, including partial thromboplastin time, Quick's prothrombin time, and platelet count, showed no significant variations between the groups.
• The study found no evidence that antithrombin III administration impacts these coagulation parameters in this population.

Conclusions:

• Early administration of antithrombin III (within the first 2 days of life) does not decrease the incidence of intraventricular hemorrhage in premature infants.
• Given the high cost of antithrombin III therapy, its clinical benefits require rigorous evaluation before widespread recommendation for neonatal care.
• Further research is warranted to explore alternative or refined therapeutic strategies for IVH prevention in preterm neonates.